Skip to main content
ZIM Laboratories Limited logo

ZIM Laboratories Limited — Investor Relations & Filings

Ticker · ZIMLAB ISIN · INE518E01015 LEI · 335800YPYG1O3ML66R52 BSE.NS Manufacturing
Open in API
Filings indexed 413 across all filing types
Latest filing 2026-05-19 Investor Presentation
Country IN India
Listing BSE.NS ZIMLAB

About ZIM Laboratories Limited

https://www.zimlab.in/

ZIM Laboratories Limited is a research-driven organization specializing in the development and manufacturing of innovative drug delivery solutions. The company focuses on enhancing the efficacy and patient compliance of generic medicines through advanced formulation technologies. Its core product portfolio includes Oral Disintegrating Films (ODF), Oral Disintegrating Tablets (ODT), pellets, and taste-masked granules. Utilizing proprietary technology platforms like Thinoral, the company provides differentiated products across various therapeutic segments, including central nervous system, cardiovascular, and gastrointestinal health. ZIM Laboratories offers end-to-end services from product development and clinical trials to commercial manufacturing. The organization serves a global clientele, providing value-added generic formulations that address specific patient needs such as ease of administration and rapid onset of action.

Recent filings

Filing Released Lang Actions
Disclosure under Regulation 30 of SEBI LODR regarding earnings presentation for Q4 & FY26.
Investor Presentation Classification · 92% confidence The document is a detailed slide deck containing financial highlights, business mix, R&D pipeline, governance updates, and strategic information presented as an "Earnings Presentation" for Q4 and FY26. It is filed under Regulation 30 of SEBI and includes charts, tables, and narrative framing as an Investor Presentation rather than a brief earnings release or the full annual/interim report. Therefore, it should be classified as an Investor Presentation.
2026-05-19 English
General Updates
Investor Presentation Classification · 95% confidence The document is a detailed Q4 & FY26 Earnings Presentation containing slide decks on financial highlights, business mix, R&D pipeline, governance, and CAPA remediation. It was filed under SEBI Regulation 30 as an enclosed investor presentation rather than a brief earnings release or mere announcement. This matches the definition of an Investor Presentation (IP).
2026-05-19 English
Please find attached a press release dated 19th May 2026 titled "ZIM Laboratories Limited announces grant of Marketing Authorization (MA) for Dabigatran Etexilate (75 mg, 110 mg &150 mg) ....
Regulatory Filings Classification · 90% confidence The document is a stock exchange filing (to BSE and NSE) consisting of a press release announcing the grant of marketing authorization for a pharmaceutical product. It is not a financial report, earnings release, management change, dividend notice, or other specific category. It serves as a general regulatory/compliance announcement. Therefore, it falls under Regulatory Filings (RNS).
2026-05-19 English
Press Release
Regulatory Filings Classification · 85% confidence The document is a corporate press release submitted to BSE and NSE announcing the grant of marketing authorization for a pharmaceutical product. It contains no financial results, accounting data, proxy materials, or report attachments. It is a general regulatory announcement/communication filed with the stock exchanges. Therefore, it falls under the broad Regulatory Filings category (RNS).
2026-05-19 English
Pursuant to Regulation 33, please find attached the Financial Results (Standalone and Consolidated) of the Company for the year ended 31.03.2026
Regulatory Filings Classification · 85% confidence The document is a compliance filing under SEBI LODR – it notifies exchanges of the Board’s approval of its audited financial statements and financial results and encloses the auditor’s report. It is not the full annual report (10-K) or a standalone audit report (AR) by itself, nor a press‐style earnings release (ER). Instead, it is a routine regulatory announcement with attachments, fitting the “Regulatory Filings” (RNS) category.
2026-05-19 English
Appointment of M/s. Dhananjay V. Joshi & Associates, Cost Accountants as the Cost Auditor for the F.Y. 2026-27
Regulatory Filings
2026-05-19 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.